Key facts
- It has raised $3.4M across 1 recorded rounds; the latest was Seed Round ($3.4M) in Mar 2022.
- descendantsDNA has filed 1 Form D with the SEC, most recently Feb 2025 ($3.4M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for descendantsDNA
Funding rounds
1 roundsAbout descendantsDNA
Developer of a whole genome sequencing platform intended to empower families' health journey. The company's platform follows a sequencing process, extracts preserved DNA, transfers it, and accurately analyses and decodes the entire genome, enabling physicians, counsellors, and assistants to help their patients achieve their longest potential healthy lifespans.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2021
- Website
- descendantsdna.com/
- Ownership
- Privately Held (backing)
descendantsDNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in descendantsDNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on descendantsDNA in its N-PORT filings yet. We sweep new filings monthly.